Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

PRLD

Prelude Therapeutics (PRLD)

Prelude Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:PRLD
DateTimeSourceHeadlineSymbolCompany
01/07/20254:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRLDPrelude Therapeutics Inc
01/03/20257:41AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRLDPrelude Therapeutics Inc
01/02/20254:09PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRLDPrelude Therapeutics Inc
12/20/20247:35AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRLDPrelude Therapeutics Inc
12/20/20247:33AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRLDPrelude Therapeutics Inc
12/11/20247:45AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRLDPrelude Therapeutics Inc
12/11/20247:30AMGlobeNewswire Inc.Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid MalignanciesNASDAQ:PRLDPrelude Therapeutics Inc
11/27/20247:30AMGlobeNewswire Inc.Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology SummitNASDAQ:PRLDPrelude Therapeutics Inc
11/06/20244:27PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PRLDPrelude Therapeutics Inc
11/06/20244:05PMGlobeNewswire Inc.Prelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:PRLDPrelude Therapeutics Inc
10/24/20247:40AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRLDPrelude Therapeutics Inc
10/24/20247:30AMGlobeNewswire Inc.Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR SymposiumNASDAQ:PRLDPrelude Therapeutics Inc
10/09/20247:30AMGlobeNewswire Inc.Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR SymposiumNASDAQ:PRLDPrelude Therapeutics Inc
09/13/202410:00AMGlobeNewswire Inc.Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 TrialNASDAQ:PRLDPrelude Therapeutics Inc
09/09/20249:02AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRLDPrelude Therapeutics Inc
09/09/20247:30AMGlobeNewswire Inc.Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024NASDAQ:PRLDPrelude Therapeutics Inc
08/12/20247:20AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PRLDPrelude Therapeutics Inc
08/12/20247:10AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRLDPrelude Therapeutics Inc
08/12/20247:01AMGlobeNewswire Inc.Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:PRLDPrelude Therapeutics Inc
07/09/20247:30AMGlobeNewswire Inc.Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated CancersNASDAQ:PRLDPrelude Therapeutics Inc
07/08/20244:02PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRLDPrelude Therapeutics Inc
06/18/20244:06PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRLDPrelude Therapeutics Inc
06/12/20246:55AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRLDPrelude Therapeutics Inc
06/11/202412:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PRLDPrelude Therapeutics Inc
06/03/20247:01AMGlobeNewswire Inc.Prelude Therapeutics to Participate in Upcoming Healthcare ConferencesNASDAQ:PRLDPrelude Therapeutics Inc
05/30/20244:29PMEdgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:PRLDPrelude Therapeutics Inc
05/16/20244:09PMEdgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:PRLDPrelude Therapeutics Inc
05/16/20244:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRLDPrelude Therapeutics Inc
05/09/20247:01AMGlobeNewswire Inc.Prelude Therapeutics to Participate in Citizens JMP Life Sciences ConferenceNASDAQ:PRLDPrelude Therapeutics Inc
05/09/202412:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PRLDPrelude Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:PRLD

Your Recent History

Delayed Upgrade Clock